Use of Novel Mobile Technology to Screen Sexual Partners for HIV and STIs

使用新型移动技术筛查性伴侣的艾滋病毒和性传播感染

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Increasing incidence of HIV and STIs among men who have sex with men (MSM) and transgender women (TGW) highlight the need for novel approaches to reducing infections-especially among individuals who do not use condoms consistently. Our prior studies on the use of rapid HIV self-testing (ST) by MSM who regularly engage in high-risk sexual behavior, show that these men are willing to use ST with partners, avoid intercourse in situations where partners test HIV-positive, and, over time tend to reduce their high-risk sexual behavior. This proposed study expands this line of research by exploring the use of a new device, the mChip dongle. Developed at the Columbia University School of Engineering, this device uses smartphone technology to analyze a drop of blood and test it for HIV and syphilis antibodies. The mChip dongle brings more precision to ST, tests for HIV and syphilis and potentially other STIs, and can capitalize on smartphone technology to provide clearer user instructions, on-hand information about HIV/STI, remote monitoring of the its use, and linkage of newly diagnosed individuals to care. For this proposed quantitative and qualitative study, we will again focus on HIV-uninfected MSM and TGW with multiple sexual partners who know how to prevent HIV infection, yet engage in high-risk sexual behavior. The Specific Aims are to: 1) Assess acceptability among MSM and TGW of using the mChip dongle to test sexual partners; 2) Optimize the smartphone app and mChip dongle for home use; and 3) Assess the feasibility of using the mChip dongle to test sexual partners, including: a) frequency of use of the mChip dongle with sexual partners over 3 months; b) factors associated with mChip dongle use or non-use; c) condom use with partners who were not screened vs. partners screened HIV or STI- negative with the mChip dongle; and d) factors associated with changes in sexual risk behavior over 3 months. The study consists of two phases. In Phase 1A, 60 participants will undergo a quantitative, qualitative, and skill-demonstration assessment (using the mChip dongle in front of the interviewer) in a single study visit. Phase 1A findings wil inform Phase 1B, which focuses on revising the smartphone app and mChip dongle for home users, as well as revisions to the Phase 2 assessment. In Phase 2A, 80 new participants will undergo a baseline quantitative and skill-demonstration assessment in order to screen for 50 participants who will be invited into the Phase 2B 3-month study. These 50 participants will be provided with an mChip dongle and given the choice to use it to screen sexual partners. After 3 months participants will undergo a quantitative and qualitative interview about experiences using (or not using) the mChip dongle with partners. This study will capitalize on a critical juncture in the development of the mChip dongle by systematically engaging its intended users in offering feedback to the engineering team on how to optimize its usability and acceptability among high-risk populations. This study will also allow us to assess the feasibility of conducting a larger and longer trial to develop and test an mChip-based harm-reduction intervention.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ivan C Balan其他文献

Ivan C Balan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ivan C Balan', 18)}}的其他基金

Integration of Electronic SBI(RT) into an HIV Testing Program to Reduce Substance Use and HIV risk Behavior among MSM in Argentina
将电子 SBI(RT) 纳入 HIV 检测计划,以减少阿根廷 MSM 的药物使用和 HIV 风险行为
  • 批准号:
    10402058
  • 财政年份:
    2022
  • 资助金额:
    $ 58.05万
  • 项目类别:
Integration of Electronic SBI(RT) into an HIV Testing Program to Reduce Substance Use and HIV risk Behavior among MSM in Argentina
将电子 SBI(RT) 纳入 HIV 检测计划,以减少阿根廷 MSM 的药物使用和 HIV 风险行为
  • 批准号:
    10669561
  • 财政年份:
    2022
  • 资助金额:
    $ 58.05万
  • 项目类别:
Use of Novel Mobile Technology to Screen Sexual Partners for HIV and STIs
使用新型移动技术筛查性伴侣的艾滋病毒和性传播感染
  • 批准号:
    9475241
  • 财政年份:
    2016
  • 资助金额:
    $ 58.05万
  • 项目类别:
Use of Novel Mobile Technology to Screen Sexual Partners for HIV and STIs
使用新型移动技术筛查性伴侣的艾滋病毒和性传播感染
  • 批准号:
    9133042
  • 财政年份:
    2016
  • 资助金额:
    $ 58.05万
  • 项目类别:
HIV-Prevention Intervention Targets in High-risk Alcohol Venues in Argentina
阿根廷高风险酒精场所的艾滋病毒预防干预目标
  • 批准号:
    7620532
  • 财政年份:
    2008
  • 资助金额:
    $ 58.05万
  • 项目类别:
HIV-Prevention Intervention Targets in High-risk Alcohol Venues in Argentina
阿根廷高风险酒精场所的艾滋病毒预防干预目标
  • 批准号:
    7694321
  • 财政年份:
    2008
  • 资助金额:
    $ 58.05万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 58.05万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 58.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了